Sihuan Pharmaceutical reported that its new gastrointestinal generic drug, Roxatidine Acetate Hydrochloride for Injection, received SFDA approval. As a first-to-market generic, it will enjoy four years of exclusivity in China. The drug, which was approved in both oral and injectible forms, is a treatment for ulcers and GI bleeding. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});